[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-342776-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-342776-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","map7-drives-emt-and-cisplatin-resistance-in-ovarian-cancer-via-wnt-catenin-signaling","MAP7 drives EMT and cisplatin resistance in ovarian cancer via wnt/β-catenin signaling","","MAP7 is investigated as a molecular driver of epithelial-mesenchymal transition (EMT) and cisplatin resistance in ovarian cancer through Wnt/β-catenin signaling. The study integrates expression analysis across multiple datasets and clinical specimens, links MAP7 to patient outcomes, and tests effects on proliferation, migration, invasion, and apoptosis. MAP7 is upregulated in tumors and associates with advanced stage, higher grade, and poor prognosis. MAP7 inhibition reduces tumor cell growth and motility while enhancing apoptosis, suppresses EMT, disrupts Wnt/β-catenin signaling, and reverses cisplatin resistance in A2780-DDP cells, highlighting nuclear MAP7’s role.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/map7-drives-emt-and-cisplatin-resistance-in-ovarian-cancer-via-wnt-catenin-signaling/342776/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/map7-drives-emt-and-cisplatin-resistance-in-ovarian-cancer-via-wnt-catenin-signaling/342776.png","ImageObject",300,407,{"name":42,"@type":43},"Aurora","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What methods does the study use to evaluate MAP7 in ovarian cancer?","Question",{"text":63,"@type":64},"It analyzes MAP7 expression across datasets and clinical specimens, assesses associations with patient outcomes, and tests MAP7 effects on ovarian cancer cell proliferation, migration, invasion, and apoptosis.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does inhibiting MAP7 affect ovarian cancer cells?",{"text":68,"@type":64},"MAP7 inhibition suppresses proliferation, migration, and invasion while promoting apoptosis and attenuating EMT and Wnt/β-catenin pathway signaling.",{"name":70,"@type":61,"acceptedAnswer":71},"Does MAP7 influence sensitivity to cisplatin?",{"text":72,"@type":64},"Yes. Downregulation of MAP7 reverses cisplatin resistance in cisplatin-resistant A2780-DDP cells, with nuclear localization suggesting a role in transcriptional regulation through β-catenin.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},342776,1790126037,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},4810365810221,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Heliyon 10 (2024) e30409  \nContents lists available at ScienceDirect  \nHeliyon  \njournal [homepage:](homepage: www.cell.com/heliyon)[ www.cell.com/heliyon](homepage: www.cell.com/heliyon)  \n| Research article\u003Cbr>MAP7 drives EMT and cisplatin resistance in ovarian cancer via wnt/β-catenin signaling\u003Cbr>Qingqing Chena, 1, Shaojing Lib, 1, Furong Fud, Qunhuan Huang c, b, **, Rong Zhang b, a, *\u003Cbr>a The Third School of Clinical Medicine,Southern Medical University, Guangzhou, 510500, China\u003Cbr>b Shanghai Fengxian District Central Hospital, 6600 Nanfeng Road, Fengxian District, Shanghai, 201400, China\u003Cbr>c Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China d Pingyang Hospital affiliated to Wenzhou Medical University, No.555, Kunao Road, Zhejiang Province, China |  |  |\n| --- | --- | --- |\n| A R T I C L E I N F O |  | A B S T R A C T |\n| Keywords: MAP7\u003Cbr>Wnt/β-catenin EMT\u003Cbr>Ovarian cancer Cisplatin resistance CBY1 |  | Methods: Our approach encompasses analyzing MAP7’s expression levels across various datasets and clinical specimens, evaluating its association with patient outcomes, and probing its influence on ovarian cancer cell dynamics such as proliferation, migration, invasion, and apoptosis. Results: We have identified significant upregulation of MAP7 in ovarian cancer tissues, which correlates with advanced disease stages, higher pathological grades, and unfavorable prognoses. Functionally, the inhibition of MAP7 suppresses cancer cell proliferation, migration, and invasion while promoting apoptosis. Notably, the silencing of MAP7 attenuates the epithelialmesenchymal transition (EMT) and disrupts Wnt/β-catenin pathway signaling—two critical processes implicated in metastasis and chemoresistance. In cisplatin-resistant A2780-DDP cells, the downregulation of MAP7 effectively reverses their resistance to cisplatin. Furthermore, the nuclear localization of MAP7 in these cells underscores its pivotal role in driving cisplatin resistance by modulating the transcriptional regulation and interaction dynamics of β-catenin. Conclusion: Our findings position MAP7 as a pivotal element in ovarian cancer advancement and cisplatin resistance, primarily through its modulation of EMT and the Wnt/β-catenin pathway. Its association with poor clinical outcomes underscores its potential as both a prognostic marker anda therapeutic target. Strategies aimed at MAP7 could represent a new frontier in combating chemotherapy resistance in ovarian cancer, emphasizing its significance in crafting complementary treatments for this disease. |\n\n1. Introduction  \nOvarian cancer is among the leading threats to women’s health globally, with its complex pathogenesis and challenging treatment options being central focuses of medical research [1]. The disease is particularly deadly due to its tendency to remain asymptomatic in  \n* Corresponding author. Shanghai Fengxian District Central Hospital, 6600 Nanfeng Road, Fengxian District, Shanghai, 201400, China.  \n** Corresponding author. Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, 274 Middle Zhijiang Road, Jing’an District, Shanghai, 200071, China.  \nE-mail addresses: [qunhuan_huang@163.com](qunhuan_huang@163.com) (Q. Huang), [zr18017807609@smu.edu.cn](zr18017807609@smu.edu.cn) (R. Zhang).  \n1 These authors contributed equally to this work and share first authorship.  \n[https://doi.org/10.1016/j.heliyon.2024.e30409](https://doi.org/10.1016/j.heliyon.2024.e30409)  \nReceived 19 March 2024; Received in revised form 24 April 2024; Accepted 25 April 2024 Available online 29 April 2024  \n2405-8440/© 2024 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license ([http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/)).  \nearly stages, leading to late diagnosis and limited treatment efficacy. According to ","cbCaih2H21bCMkNw","https://ap.wps.com/l/cbCaih2H21bCMkNw","pdf",12884981,15,"English","# Introduction\n## MAPs and microtubule-related regulation\n## MAP7: function and relevance to cancer progression","[{\"question\":\"What methods does the study use to evaluate MAP7 in ovarian cancer?\",\"answer\":\"It analyzes MAP7 expression across datasets and clinical specimens, assesses associations with patient outcomes, and tests MAP7 effects on ovarian cancer cell proliferation, migration, invasion, and apoptosis.\"},{\"question\":\"How does inhibiting MAP7 affect ovarian cancer cells?\",\"answer\":\"MAP7 inhibition suppresses proliferation, migration, and invasion while promoting apoptosis and attenuating EMT and Wnt/β-catenin pathway signaling.\"},{\"question\":\"Does MAP7 influence sensitivity to cisplatin?\",\"answer\":\"Yes. Downregulation of MAP7 reverses cisplatin resistance in cisplatin-resistant A2780-DDP cells, with nuclear localization suggesting a role in transcriptional regulation through β-catenin.\"}]","MAP7 drives EMT and cisplatin resistance in ovarian cancer via wnt/β-catenin signaling | PDF",1790048197,38,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b2972dbbc80e70fae5187b300a91f973.webp",983,1341,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/326f4d7a34df9a710011e885b366bbc9.webp",982,1340,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/814478db2f6bd9cb434715b57cb2981d.webp",981,1338,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cc72f10da061e5cca3265e995dd663a6.webp",980,1337]